Showing results (171-180 of 389) with videos related to
Sort By:
Pageof 39
International Journal of Clinical Oncology|April 7, 2021
First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysisKatsuyuki Hotta, Makoto Nishio, Haruhiro Saito, et al.Cancer Chemotherapy and Pharmacology|July 20, 2005
Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancerIsamu Okamoto, Akinobu Hamada, Yusuke Matsunaga, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplificationTakafumi Okabe, Isamu Okamoto, Sayaka Tsukioka, et al.Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodiesYasuto Yoneshima, Kentaro Tanaka, Yoshimasa Shiraishi, et al.Investigational New Drugs|October 21, 2010
Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumorsIsamu Okamoto, Toshio Shimizu, Masaki Miyazaki, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2012
A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancerKazuko Sakai, Isamu Okamoto, Ken Takezawa, et al.Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancerShinichi Kimura, Taishi Harada, Kayo Ijichi, et al.Anticancer Research|February 4, 2019
Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung CancerNaoki Kubo, Taishi Harada, Yoshimasa Shiraishi, et al.Scientific Reports|June 18, 2021
Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosisYasuto Yoneshima, Eiji Iwama, Shingo Matsumoto, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 2, 2008
A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancerNoriyuki Ebi, Hiroshi Semba, Sho J I Tokunaga, et al.Pageof 39